FTSE 100 falters as food retailers dive on Tesco results

The FTSE 100 gave back some of this week’s gains on Wednesday as short-term profit taking and concerns around the health of the UK consumers hit the supermarkets.

In a FTSE 100 index dominated by overseas revenues, Wednesday’s trade was dictated by UK facing companies as the UK’s supermarkets and retailers sank following Tesco’s interim update.

Tesco said their profit would be towards the lower end of guidance and revealed falling margins as the cost of living crisis drove consumers to budget lines.

Tesco shares fell some 3.6% while premium retailer Ocado saw its shares sink 5.8% as investors extrapolated Tesco’s results across the rest of the market. Ocado was the FTSE 100’s worst performer at the time of writing.

“Supermarkets are no strangers to dealing with cost-of-living pressures, there’s been an all-out price war in the industry for some years now,” said Matt Britzman, Equity Analyst at Hargreaves Lansdown.

“Amongst the larger players, Tesco’s arguably been one of the standout businesses in the battle against low-cost outfits but pressures on consumer spending can only build for so long before something must give.”

“That pain’s slowly starting to feed into performance, as shopping behaviours continue to normalise from bumper levels seen over the pandemic and inflation keeps costs high – that’s meant full year profit guidance got a slight downgrade toward the bottom end of the previous range.”

Sainsbury’s shares were 4.3% weaker ahead of their interim results in early November.

Truss Speech

Liz Truss’s conservative conference speech failed to ignite any further confidence in UK assets as GBP/USD fell 1% to 1.1360. Investors are awaiting the OBR’s economic assessment to gauge the impact on the UK’s finances and the Prime Minister’s speech provide no respite for concerns her mini-budget would cause economic difficulties in the short-term.

UK housebuilders have been one of the most heavily hit sectors since Kwasi Kwarteng’s fiscal announcement, and today Persimmon, Barratts Developments and Taylor Wimpey ended a three-day rally from their worst levels last week.

The FTSE 100 was down 1% to 7,015 at the time of writing.

Tesco’s interims reflect a price war amid the cost of living crisis

Tesco is taking on discounters Aldi and Lidl in a price war as the cost of living crisis drives consumers to seek out better value products.

This was reflected in a growing revenue but lower gross and operating profit as Tesco sells an increasing amount of budget items.

Statutory revenue including fuel for the 26 weeks to 27th August was £32,456m, up from £30,416m in the same period a year prior.

However, despite group revenue growing 6.7%, gross profit fell to £1,723m from £2,448m a year prior.

The biggest impact on gross profit was an impairment charge caused by higher discounts. Statutory operating profits fell 43.6% to £736m.

Tesco have taken discounters Aldi and Lidl head-on with Low Everyday Prices and Clubcard Prices and is well placed to maintain their market share, but the retailer will see their margins suffer as a result.

“Tesco is in a better position to face competition from discounters. Our experts say Tesco has strong pricing power, a sufficiently wide range of products for customers to trade down in the store, and a big advantage in its Clubcard loyalty scheme,” said Orwa Mohamad, a Consumer Sector Analyst at Third Bridge.

“Aldi and Lidl may be gaining market share but this is mainly from Morrisons and Sainsbury’s as savvy shoppers hunt for bargains in the cost-of-living crisis.”

As well as revealing damaging impairments charges in their interims, Tesco also suggested the outlook was becoming even tougher as the cost of living crisis and higher interest rates further squeezed spending. Stopping short of an all out profit warning, Tesco said they saw profits towards the lower end of their previous retail operating profit guidance of between £2.4bn and £2.5bn.

“The uncertainty is palpable in the company’s outlook comments and inevitably this will make the market rather nervous,” said AJ Bell investment director, Russ Mould.

“On the plus side, Tesco is entering a difficult period with a decent market position and solid balance sheet.”

“However, it is hard to see the coming months as anything other than extremely difficult, with cost inflation affected not only by higher energy and labour costs but also the cost of importing goods from overseas thanks to lower sterling.”

AIM movers: Genedrive FDA pre-submission and PCF Bank suspends lending

0

Genedrive (LON: GDR) has made a pre-submission to the US FDA for the MT-RNR1 ID kit. The MT-RNR1 assay is a rapid point-of-care test for screening infants for a genetic variant that will cause life-long hearing loss if they are given certain antibiotics. There is no exact comparative test, and the FDA will provide feedback on what will be required in the final submission. The share price has jumped 31.8% to 14.5p.

Omega Diagnostics (LON: ODX) says a draft evaluation report for the VISITECT CD4 test suggests that the test has high diagnostic accuracy and it should meet criteria for WHO Prequalification. Once WHO Prequalification happens the £4m in an escrow account following the sale of VISITECT CD4 to Accubio will be released to Omega Diagnostics. That could happen in the next six months. This should boost the cash position to £6m by the end of March 2023. The shares rose by 21.7% to 2.8p, which values the company at £6.7m.

Concurrent Technologies (LON: CNC) has launched its first systems product. Helios is a ruggedised vision computer system. The share price is 7.59% higher at 78p.

Arbuthnot Banking (LON: ARBB) says full results should be ahead of market expectations of a £13m pre-tax profit. Base rate rises have a positive effect on results. Changes to deposit rates lag the rises in interest rates. Credit criteria are being tightened. The share price improved by 7.38% to 800p.

City Pub Group (LON: CPC) has launched its share buy back programme. An initial £2m has been set aside and there is an option for an additional £1m. The programme lasts until 20 September 2023. The shares rose 7% to 61p.

PCF Group (LON: PCF) has suspended new lending by PCF Bank while it is trying to raise additional finance. Last week, Castle Trust Capital decided not to bid for PCF. Sales of assets and other options to raise money are being considered. There will be further cost cutting. The shares have fallen by one-third to 1.5p.

Serinus Energy (LON: SENX) says that the Moftinu Nord-1 well in Romania was unsuccessful. This knocked 26.1% off the share price leaving it at 8.5p. The well cost $867,000 and the gas found did not warrant flow testing. Arden expects management to assess the results of its Romanian drilling before making a decision on whether to drill a third well. A drilling rig has been secured for Tunisia in the fourth quarter. This will be deployed to Sabria and this drilling could significantly increase production.

Horizonte Mining (LON: HZM) announced a fundraising on Tuesday evening and the size of the placing was increased from £61.7m to £70.5m at 90.5p a share. The share price fell 10% to 89.5p. This larger fundraising has also reduced the contribution from major shareholder La Mancha from £23.8m to £22m. The cash will help to complete the construction of the Araguaia nickel project in Brazil. Total capital cost has increased from $477m to $537m. First production is scheduled for the first quarter of 2023.

Netcall’s cloud-based progress

0

Customer engagement systems supplier Netcall (LON:NET) is accelerating organic growth thanks to the investment it has previously put into its cloud-based technology. Recurring revenues are rising, and cash generation is strong. Annual contract value grew from £18.5m to £24.2m over the past 12 months.

Netcall gained an $19m three-year cloud subscription contract during the period, but only £300,000 was recognised in the year to June 2022. Group revenues were 12% ahead at £30.5m, with cloud revenues growing 30% to £10.7m. Control of overheads helped underlying pre-tax profit from £2.6m to £3.9m. The dividend has been raised from 0.37p a share to 0.54p a share.

Netcall has moved into the transport and utility sectors and is increasing the number of partners. The market for automation and customer engagement is estimated at $20bn and is growing by 20% a year. Research by McKinsey & Co suggests that one-quarter of processes will be automated within five years.

Canaccord Genuity has upgraded its pre-tax profit forecast for this year from £5m to £5.7m. The Business Growth Fund has exercised options relating to its loan note and the loan will be repaid. That boosts profit and earnings. Net cash could reach £21m by the end of June 2023.

Netcall has risen by one-fifth so far this year, making it one of the better performers on AIM. At 82.5p, the shares are trading on 29 times prospective earnings.

Tesco, First Class Metals, and Deltic Energy with Alan Green

Alan Green joins the UK Investor Magazine Podcast for discussion around key market themes and a number of UK equities.

We look at the FTSE 100 and the dynamics driving trade as markets access the progress of the UK government.

Tesco reported interims this morning and provided an insight into the health of the UK consumer and the battle between the traditional top 4 supermarkets and the discounters.

First Class Metals floated this year at 10p and now trade just beneath 15p following a raft of positives updates and corporate developments. As a shareholder, Alan outlines the company’s investment proposition.

UK Natural Gas has won the spotlight during the energy crisis and Deltic Energy have the potential to add to the UK’s supply if their exploration joint venture with Shell proves successful.

Horizonte Minerals shares fall below placing price after institutional only fundraise

Horizonte Minerals shares dropped on Wednesday after the group completed an oversubscribed £70.5m fundraise to help fund the development of their Brazilian nickel and achieving assets first production at Araguaia in 2024.

The Horizonte Minerals share price fell beneath the 90.5p placing price on Wednesday to trade at 88p at the time of writing.

Due to restrictions on making the offer available to retail investors, meaning Horizonte would have to produce another prospectus at a cost, the company opted to exclude retail from the offer.

However, any retail investors that would have liked to participate in the offer can now buy Horizonte Minerals shares at a lower price on the open market.

There was strong demand for the offer from institutions which was oversubscribed with the gross proceeds increasing from an initial target of £61.7m to £70.5m.

“I am pleased to announce the completion of the Fundraise. I would like to thank all existing shareholders for their continued support and welcome our new shareholders as we work towards first production at Araguaia in Q1 2024 and in parallel progress feasibility work at Vermelho,” said Jeremy Martin, Chief Executive Officer of Horizonte.

“Significant progress has been made since we broke ground at Araguaia in May and we remain well positioned to transition into a scalable Tier 1 nickel producer. We look forward to updating the market as construction advances at Araguaia.”

Omega Diagnostics shares jump on positive VISITECT® data

Omega Diagnostics shares had a storming start to Wednesday’s session after the company announced positive data from VISITECT® CD4 Advanced Disease Rapid Test evaluations.

Omega Diagnostics agreed the sale of VISITECT® CD4 to Accubio Limited in August and are set to receive an additional £4m should there be a successful outcome of a clinical study in Kenya.

The study analysed 300 specimens and concluded that the VISITECT® CD4 Advanced test showed high sensitivity of 96.0%. This will likely satisfy WHO pre-qualification status and can be included in the VISITECT® Performance Evaluation.

 Omega Diagnostics shares were 18% higher at 2.7p at the time of writing.

“We are extremely pleased to receive this draft report, detailing that the test has shown high diagnostic accuracy. Whilst we have no visibility of the WHO pre-qualification requirements, it is encouraging to formally receive these positive results,” said Jag Grewal, CEO of Omega Diagnostics.

“If the VISITECT® CD4 Advanced Disease test successfully meets all WHO pre-qualification requirements, it will continue to be made available for sale by Accubio and the Company will receive the full £4.0m of deferred consideration. We look forward to updating shareholders on the outcome in due course.”

Gyllenhammar acquires stake in Pressure Technologies

0

Peter Gyllenhammar has taken a stake in Pressure Technologies (LON: PRES) following the share price slump after last week’s trading statement.

Premier Miton more than halved its stake in Pressure Technologies from 9.99% to 4.59% – Miton UK MicroCap Trust has cut its stake in to 2.29% and this was being reduced before the trading statement. Rockwood Strategic, which moved from AIM to the Main Market last week, holds 13.8%.

Pressure Technologies had a disappointing second half. There will be a full year loss and the engineering company will also breach covenants on its bank facility. More cash is required.

Net debt was £5.4m at the interim stage and it could be £3.9m at year-end. The finance could come from a share issue or a convertible issue or another form of funding. Management is talking to Lloyds about the bank facility.

Supply chain and manufacturing problems hampered progress with defence contracts, while oil and gas companies delayed orders. On top of this costs have been rising.

Demand for the Chesterfield Special Cylinders remains strong with potential from the hydrogen sector. Precision Machined Components should benefit from a recovery in oil and gas demand.

Management believes that Pressure Technologies can return to profit in 2022-23 on the back of improving order levels. VSA forecasts a 2022-23 pre-tax profit of £200,000, recovering to £1.7m the following year.

Forecast net assets are £15.4m, including the company’s main factory. The share price has fallen from 63p to 27p since the trading statement. That values Pressure Technologies at £8.5m, which is low considering the asset backing. However, the concerns about cash are likely to hold back the share price in the short-term.

FTSE 100 surges in broad rally, Legal & General reassures investors

The FTSE 100 surged on Tuesday as bargain hunters stepped in to pick up beaten down stocks after a strong session in the US overnight.

The FTSE 100 flew back through 7,000 to trade as high as 7,040 around midday on Tuesday.

“US markets finally got something to cheer about in the first session of the fourth quarter. Both the S&P 500 and NASDAQ posted their biggest daily increases since August as US Treasury yields pulled back 0.18 percentage points,” said Matt Britzman, Equity Analyst at Hargreaves Lansdown.

However, Britzman warned while optimism is returning to markets, it may be short-lived.

“Whilst rallies in most global indices is certainly a welcome reprieve, underlying issues very much remain,” Britzman said.

Nonetheless, FTSE 100 blue chips that had been heavily hit since the mini-budget became the target of investors seeking out bargains.

Hargreaves Landsown was the top riser gaining 6%, while Entain, Melrose and Legal & General were all up over 5% higher.

Legal & General issued a trading statement on Tuesday and focused on the strength of their cash position and solvency. Legal & General shares had fallen sharply last week as investors fretted about their exposure to UK government bonds during high periods of volatility.

“It’s not often that Legal & General has to calm investors’ nerves, given it is meant to be a steady as she goes type of business. Its shares enjoyed a relief rally after reassuring the market that it hasn’t been a forced seller of gilts or bonds, and that it continues to have a good solvency coverage ratio,” said Danni Hewson, financial analyst at AJ Bell.

Slow interest rate hikes?

With a backdrop of rising prices and the threat of a recession, the large jumps in interest rates have been unnerving markets.

The Australian central bank hiked rates by 25bps overnight – a lower increase than expected – and raised the question of a near term peak in the global hiking cycle.

“The cash rate has been increased substantially in a short period of time,” said RBA Governor Philip Lowe in a statement.

If the Australian central bank’s decision and subsequent comments prove to be the beginning of a trend of central banks slowing the pace of hiking, it may begin to improve sentiment around the depth of any recession and bring investors back into equities.

However, inflation is still soaring in many countries and Australia is a somewhat insular economy compared those of Western Europe and the US.

AIM movers: Watkin Jones slumps and no bid for GB Group

0

Two deals were not completed by student accommodation and build to rent developer Watkin Jones (LON: WJG) before the end of September and they have knocked at least 10% off 2021-22 profit to around £49m. The dividend could be trimmed to 7.8p a share, so that it is twice covered by earnings. There are also cost pressures and interest rate rises will hamper future profitability. This led to a one-third cut in 2022-23 pre-tax profit forecast to £50m. Demand for student accommodation and build to rent remains strong but margins will come under pressure. Net cash is £75m. The share price has slumped by one-third to 100.3p.

Interim results from medical devices supplier Inspiration Healthcare (LON: IHC) show a small dip in revenues from £20.9m to £20.5m, although higher full year revenues are still anticipated. This is backed up by the order book. Sales mix and higher costs have hit margins. Stock levels have increased to offset rising prices. Along with capital investment, this led to a fall in cash to £3.3m. Cenkos has trimmed its revenues forecast but maintained profit expectations. The share price has fallen 16% to 73.5p.

GTCR is no longer considering a bid for GB Group (LON: GBG) and the shares have fallen 14.2% to 527.5p.

Allergy Therapeutics (LON: AGY) has paused production at its Worthing manufacturing site in order to make operational improvements. This should improve quality and increase production capacity. Clinical trials will not be affected, but there will be an impact on revenues. That knocked 10.5% off the share price to 17p.

A trading statement from Character Group (LON: CCT) indicates that figures for the year to August 2022 will be in line with expectations, but the new financial year will be tougher due to the weakness of sterling and consumer spending concerns. There has been a large increase in inventories, which has reduced cash to £15.1m. Allenby expects a 2021-22 pre-tax profit of £11.25m, but it has halved the forecast for next year to £5.5m. A total dividend of 17p a share is forecast for 2021-22. The shares fell 9% to 445p.

ECR Minerals (LON: ECR) has completed nearly three-quarters of the sampling programme at the Lolworth Range gold prospect in north Queensland. The share price fell 3.57% to 0.675p.

N4 Pharma (LON: N4P) has completed initial in vitro testing of its Nuvec delivery system loaded with two generic siRNA probes at the same time and both were able to significantly silence their respective targets. This will help discussions with potential partners. Work continues on a treatment for lung cancer. The N4 Pharma share price rose 10% to 2.2p.

Share buybacks are helping to maintain a strong share price at Shoe Zone (LON: SHOE) even though they have generally been in modest numbers.  The shares are 10.6% higher at 177.5p.

Align Research has published a report on tantalum project developer Kazera Global Investments (LON: KZG) and set a price target of 4.55p. The share price is 9.1% ahead at 0.9p.

The Catenae Innovations (LON: CTEA) share price has more than recovered the loss after it returned from suspension on 30 September. The suspension price of the digital media company was 0.275p and it returned from suspension at 0.175p but had got back to 0.275p by Monday. The price has risen a further 9.1% to 0.3p.